Arcos-Sacramento Víctor Gildardo, Sampieri Clara Luz, Sandoval-Lozano Víctor Hugo, Orozco-Ortega Rubén Arturo, Acuña-Hernández Mariel Alejandra, Morales-Romero Jaime, Hernández-Hernández Magda Elena, Rodríguez-Hernández Arturo
Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México.
Secretaría de Salud del Estado de Veracruz, Xalapa, Veracruz, México.
PeerJ. 2020 Dec 16;8:e10474. doi: 10.7717/peerj.10474. eCollection 2020.
Chronic kidney disease is one of the most common complications of type 2 diabetes mellitus (T2DM), causing an increased risk of cardiovascular morbidity and mortality. Matrix metalloproteinase (MMP) activity has been proposed as useful biomarker for diabetic renal and vascular complications.
A cross-sectional study was conducted among T2DM patients who attended a public secondary hospital in Mexico. We performed clinical, biochemical, and microbiological assessments, as well chronic kidney disease diagnosis according to the KDIGO guideline. Urinary MMP-9 was quantified by ELISA and adjusted using urinary creatinine (UCr).
A total of 111 patients were included. Most participants were women (66%). Mean age was 61 ± 10 years and median T2DM duration was estimated at 11 years. Through multivariate analysis, MMP-9/UCr was found to be associated with albumin concentration and albumin to creatinine ratio.
Validation of non-invasive biomarkers of chronic kidney disease among T2DM patients is necessary. Here, we demonstrate MMP-9/UCr as a potential biomarker of albumin concentration and albumin to creatinine ratio in Mexican patients with T2DM.
慢性肾脏病是2型糖尿病（T2DM）最常见的并发症之一，会增加心血管疾病发病和死亡风险。基质金属蛋白酶（MMP）活性已被认为是糖尿病肾脏和血管并发症的有用生物标志物。
对墨西哥一家公立二级医院的T2DM患者进行了一项横断面研究。我们进行了临床、生化和微生物学评估，并根据KDIGO指南进行了慢性肾脏病诊断。通过酶联免疫吸附测定法对尿MMP-9进行定量，并使用尿肌酐（UCr）进行校正。
共纳入111例患者。大多数参与者为女性（66%）。平均年龄为61±10岁，T2DM病程中位数估计为11年。通过多变量分析，发现MMP-9/UCr与白蛋白浓度和白蛋白与肌酐比值相关。
有必要对T2DM患者慢性肾脏病的非侵入性生物标志物进行验证。在此，我们证明MMP-9/UCr是墨西哥T2DM患者白蛋白浓度和白蛋白与肌酐比值的潜在生物标志物。
